Natera’s blood test analyzes cell-free DNA to screen for several cancer types from a single sample.
Related to this article
Pan-cancer study shows age-based germline testing misses most inherited cancer variants, supporting broader genetic screening to guide treatment and family risk.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Addressing Disparities in Stem Cell Transplant for Myeloma
2
Evaluating a Virtual Care Navigation Program for Enhanced Oral Oncolytics Management
3
Trials of Bispecifics in Smoldering Myeloma Look Beyond Delaying Progression
4
Opamtistomig Earns FDA Fast Track in First-Line Biliary Tract Cancer
5